Safety and Regulatory Aspects of Obesity Drugs

 Dr. David Orloff
 Executive Director of Regulatory Affairs
Medpace
 

 

 Dr. Orloff discusses the current and potential future regulatory issues for obesity and diabetes drugs, how FDA and industry is moving toward levels of safety for these drug classes.  
 
 

Challenges Sponsors Face in Diabetes Trials

ePRO Use in Obesity and Hypertension Trials

Recorded Webcasts from the European Association for the Study of Diabetes Annual Meeting, October 2009

FDA Scientists Recognized at Diabetes Technology Meeting

 American Association of Diabetes Educators

American Diabetes Association, Professional Section

European Association for the Study of Diabetes

Clinical Trials for Type II Diabetes in Adults

Clinical Trials for Type II Diabetes in Children

Recent Study Pinpoints Weight Gain in Children Using Antipsychotics

International Association for the Study of Obesity

 European Association for the Study of Obesity

Clinical Trials for Metabolic Syndrome in Adults